1.5 CE Test Hours: Type 2 Diabetes: A Pharmacologic Update
نویسندگان
چکیده
منابع مشابه
Pharmacologic Management of Type 2 Diabetes: 2016 Interim Update.
The initial draft of this commentary was prepared by Ronald Goldenberg MD, FRCPC, FACE, Maureen Clement MD, CCFP, Amir Hanna MB, BCh, FRCPC, FACP, William Harper MD, FRCPC, Andrea Main BScPhm, CDE, Ravi Retnakaran MD, MSc, FRCPC, Diana Sherifali RN, PhD, CDE, Vincent Woo MD, FRCPC, Jean-Francois Yale MD, CSPQ, FRCPC, and Alice Y.Y. Cheng MD, FRCPC, on behalf of the Steering Committee for the Ca...
متن کاملPharmacologic treatment of type 2 diabetes.
s of the 62nd ADA Scientific Sessions, Diabetes 51 [Suppl. 2], 2002). In the former group, insulin sensitivity, acute insulin responses to IV glucose, or glucose levels after OGTT did not change significantly 8 months after the end of the trial, while the latter group showed 26 and 39% falls in insulin sensitivity and insulin response and a 10% increase in glucose levels during the OGTT. Twenty...
متن کاملPharmacologic therapy for type 2 diabetes mellitus.
Type 2 diabetes mellitus is a chronic metabolic disorder that results from defects in both insulin secretion and insulin action. An elevated rate of basal hepatic glucose production in the presence of hyperinsulinemia is the primary cause of fasting hyperglycemia; after a meal, impaired suppression of hepatic glucose production by insulin and decreased insulin-mediated glucose uptake by muscle ...
متن کاملAddendum to policies, guidelines and consensus statements: pharmacologic management of type 2 diabetes: 2015 interim update.
An interim update of the chapter titled Pharmacologic Management of Type 2 Diabetes in the 2013 Clinical Practice Guidelines was recently published in Canadian Journal of Diabetes; it incorporates the sodium glucose linked transporter 2 (SGLT2) inhibitor class (1). Since the publication of the update, another SGLT2 inhibitor has received notice of compliance from Health Canada (2). The article’...
متن کاملPolicies, Guidelines and Consensus Statements: Pharmacologic Management of Type 2 Diabetes-2015 Interim Update.
The initial draft of this commentary was prepared by William Harper MD, FRCPC, Maureen Clement MD, CCFP, Ronald Goldenberg MD, FRCPC, FACE, Amir Hanna MB, BCh, FRCPC, FACP, Andrea Main BScPhm, CDE, Ravi Retnakaran MD, MSc, FRCPC, Diana Sherifali RN, PhD, CDE, Vincent Woo MD, FRCPC, Jean-François Yale MD, CSPQ, FRCPC, and Alice Y.Y. Cheng MD, FRCPC on behalf of the Steering Committee for the Can...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: AJN, American Journal of Nursing
سال: 2019
ISSN: 0002-936X
DOI: 10.1097/01.naj.0000554009.84637.8a